Примери за използване на Appropriate medical therapy на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Appropriate medical therapy should be administered as needed.
ZALTRAP/FOLFIRI should be discontinued and appropriate medical therapy should be administered.
Initiate appropriate medical therapy and monitor as clinically indicated.
If SJS or TEN occur, ADCETRIS should be discontinued and appropriate medical therapy should be administered.
Appropriate medical therapy, which could include paracetamol, intravenous H1 and/or H2 blockers, and low dose intravenous pethidine.
If such a reaction develops, discontinue the medication and institute appropriate medical therapy.
If SJS/TEN occur, appropriate medical therapy should be administered.
In case of a severe infusion reaction, ipilimumab infusion must be discontinued and appropriate medical therapy administered.
Most of these, including severe reactions,resolved following initiation of appropriate medical therapy or withdrawal of avelumab(see“Description of selected adverse reactions” below).
Patients with active infections occurring during treatment with pembrolizumab were managed with appropriate medical therapy.
Most of these, including severe reactions,resolved following initiation of appropriate medical therapy or withdrawal of cemiplimab(see“Description of selected adverse reactions” below).
Most of these patients showed improved symptoms and/ orleft ventricular function following appropriate medical therapy.
Most of these, including severe reactions,resolved following initiation of appropriate medical therapy or withdrawal of pembrolizumab(see“Description of selected adverse reactions” below).
The temsirolimus infusion should be interrupted in all patients with severe infusion reactions and appropriate medical therapy administered.
Most of these, including severe reactions,resolved following initiation of appropriate medical therapy or withdrawal of ipilimumab(see section 4.4 for management of immune-related adverse reactions).
If such a reaction develops during treatment with ViraferonPeg,discontinue treatment and institute appropriate medical therapy immediately.
If this occurs,therapy must be discontinued and appropriate medical therapy instituted immediately.
Most patients who developed CHF during mBC trials showed improved symptoms and/or left ventricular function following appropriate medical therapy.
Most of these, including severe reactions,resolved following initiation of appropriate medical therapy or withdrawal of IMFINZI.
In case of a severe or life-threatening infusion reaction, the nivolumab ornivolumab in combination with ipilimumab infusion must be discontinued and appropriate medical therapy administered.
If SJS or TEN occur, treatment with brentuximab vedotin should be discontinued and appropriate medical therapy should be administered.
Strensiq administration should be interrupted in any patient experiencing severe injection reactions and appropriate medical therapy administered.
If this occurs,ropeginterferon alfa-2b therapy must be discontinued and appropriate medical therapy instituted immediately.
If an acute hypersensitivity reaction(e. g., urticaria, angioedema, bronchoconstriction, anaphylaxis) develops,Rebetol must be discontinued immediately and appropriate medical therapy instituted.
In the event of a severe reaction,Benlysta administration must be interrupted and appropriate medical therapy administered(see section 4.2).
If an acute hypersensitivity reaction(e. g., urticaria, angioedema, bronchoconstriction, anaphylaxis)develops, Ribavirin must be discontinued immediately and appropriate medical therapy instituted.
In case of a severe infusion reaction,nivolumab infusion must be discontinued and appropriate medical therapy administered.
Monitoring of blood cholesterol and triglycerides prior to the start of Afinitor therapy and periodically thereafter,as well as management with appropriate medical therapy, is recommended.
In the event of prolonged orpersistent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered.
Soliris administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered.